SCHEMBL8537491

SCHEMBL8537491

C=Cc1cc(/C=C2\SC(=S)N(CCCOC)C2=O)cc(C=C)c1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 2/20 0.55
TAS2R14 Q9NYV8 1/20 0.50
MAPT P10636 6/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
CTNNB1 P35222 2/20 0.48
RAB9A P51151 2/20 0.48
TCF4 P15884 1/20 0.48
NPC1 O15118 1/20 0.48
USP2 O75604 1/20 0.48
PSMD14 O00487 2/20 0.48
POLB P06746 2/20 0.48
NAT1 P18440 1/20 0.47
MAPK1 P28482 4/20 0.46
ALDH1A1 P00352 3/20 0.46
PDE4B Q07343 2/20 0.45
NCOA3 Q9Y6Q9 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
XBP1 P17861 1/20 0.44
MCHR1 Q99705 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8537493 1.00 HSD17B3 (0.55) HSD17B3TAS2R14MAPTMEN1KMT2A
SCHEMBL7704006 0.83 HSD17B3 (0.55) HSD17B3TAS2R14MAPTMEN1KMT2A
SCHEMBL7704002 0.83 HSD17B3 (0.55) HSD17B3TAS2R14MAPTMEN1KMT2A
SCHEMBL12008469 0.72 CTNNB1 (0.79) TAS2R14MAPTMEN1KMT2ACTNNB1
SCHEMBL3893517 0.70 MEN1 (0.69) MAPTMEN1KMT2ARAB9ANPC1
SCHEMBL3893522 0.70 MEN1 (0.69) MAPTMEN1KMT2ARAB9ANPC1
SCHEMBL20837904 0.70 MAPT (0.65) TAS2R14MAPTMEN1KMT2ACTNNB1
SCHEMBL12008561 0.70 CTNNB1 (0.68) TAS2R14MAPTMEN1KMT2ACTNNB1
SCHEMBL12008449 0.70 TAS2R14 (0.76) TAS2R14MAPTMEN1KMT2ACTNNB1
SCHEMBL12217961 0.69 MEN1 (0.67) HSD17B3MAPTMEN1KMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0434394-B1 Compounds for treating inflammatory bowel disease LILLY CO ELI (US) 1998-08-05 EP disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
US-5387690-A Method of treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1995-02-07 US disclosed
US-5216002-A Using benzyl substituted rhodanine derivatives as pure enantiomeric form ELI LILLY AND COMPANY (US) 1993-06-01 US disclosed
EP-0434394-A2 Compounds for treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1991-06-26 EP disclosed